

Reply to comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience

Sir,

We thank you for your interest in our paper and agree with your concerns.^[1,2] All the patients were treated at our institute from the beginning. The definition of recalcitrance/resistance has been mentioned in the text. As this is a retrospective analysis of patients followed over many years, some even before the introduction of antivascular endothelial growth factors in ophthalmology, it is not possible for us to fit all the cases into defined criteria for switching agents, stopping, or continuing treatment. The reason for introducing recurrent cases to aflibercept was to ascertain the possibility of achieving an end point in treatment or at least an increase in the treatment-free interval. Failure to achieve either of the two resulted in a switch

back to the original drug as long as the eye had useful vision. We agree that financial issues are important which is why our study had only ten patients, those who could afford the injection and not all cases that were resistant or recalcitrant. This particular study was not intended to test the use of either aflibercept or ziv-aflibercept as primary treatment of polypoidal choroidal vasculopathy; hence, we would not like to extrapolate our results in that direction.

Financial support and sponsorship

Nil

Conflicts of interest

There are no conflicts of interest.

*Aditya Bansal, Muna Bhende, Tarun Sharma,
Pramod Bhende, Suchetana Mukherjee¹*

Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, ¹Vitreoretinal Services, Aditya Birla Sankara Nethralaya, Kolkata, West Bengal, India

Correspondence to: Dr. Muna Bhende,
Sankara Nethralaya, 18/41, College Road, Nungambakam,
Chennai - 600 006, Tamil Nadu, India.
E-mail: drmuna@snmail.org

References

1. Kathiriya V, Kanhere M, Gala Y, Ramchandani S. Comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. *Indian J Ophthalmol* 2018;66:348-9.
2. Bansal A, Bhende M, Sharma T, Bhende P, Mukherjee S. Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. *Indian J Ophthalmol* 2017;65:758-60.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Access this article online	
Quick Response Code:	Website: www.ijo.in
	DOI: 10.4103/ijo.IJO_1093_17

Cite this article as: Bansal A, Bhende M, Sharma T, Bhende P, Mukherjee S. Reply to comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience. *Indian J Ophthalmol* 2018;66:349-50.

© 2018 Indian Journal of Ophthalmology | Published by Wolters Kluwer - Medknow